ライフサイエンスコーパス: noninferior

1 isclassifying inferior treatment regimens as noninferior.

2 The primary end point was noninferior (6% margin) disease-free survival.

3 tudy explored whether antibody responses are noninferior after 2 versus 3 doses in girls.

4 TAVR was a noninferior alternative to surgery in patients with seve

5 DEVICE is a reasonable noninferior alternative to warfarin for stroke preventio

6 according to a T&E regimen was statistically noninferior and clinically comparable with a monthly reg

7 scatheter aortic valve replacement (TAVR) is noninferior and may be superior to surgical aortic valve

8 icitabine (F/TAF) was recently approved as a noninferior and potentially safer option than tenofovir

9 and dabigatran (an antithrombin agent) were noninferior and probably safer than conventional anticoa

10 dy assessing whether experimental therapy is noninferior, and if met, superior, to conventional treat

11 The 200-mg regimen was noninferior, and the 300-mg regimen was superior, to eno

12 cal power to assess whether lixisenatide was noninferior as well as superior to placebo, as defined b

13 Reader accuracy with IC-IR was noninferior at 50% (100 mAs [effective]) and 25% (300 mA

14 icagrelor monotherapy after 1-month DAPT was noninferior, but not superior, to conventional treatment

15 arge vessel stenting, BP-DES appeared barely noninferior compared with DP-DES and more effective than

16 Laparoscopic resection was noninferior compared with open resection for the rate of

17 ints; 95% CI, -2.5 to 5.6 points), which was noninferior compared with that of the liberal-strategy g

18 average knowledge gain, 6.9%; SD, 18.2) were noninferior compared with those who completed 1 month of

19 Noninferior control of inflammation, defined as absence

20 f CPR skill retention, VO training yielded a noninferior difference in CC rate compared with VSI trai

21 ted liver scans, lower-dose ANLM images were noninferior (difference: +0.015 [95% CI: -0.077, 0.106])

22 rest/stress SPECT-MPI (n=81), CCTA/rCTP had noninferior discriminatory value to CCTA/SPECT-MPI (area

23 10 mg/kg L-AmB was well tolerated and led to noninferior EFA compared to 14 days of 3 mg/kg/day L-AmB

24 Lower doses of zinc had noninferior efficacy for the treatment of diarrhea in ch

25 Doravirine (DOR) demonstrated noninferior efficacy to darunavir plus ritonavir (DRV+r)

26 dose combination (DOR/3TC/TDF), demonstrated noninferior efficacy to DRV+r and EFV as assessed by the

27 At week 48, DOR demonstrated noninferior efficacy to DRV+r and EFV, with 84.1% of DOR

28 two tenofovir prodrugs (TAF and TDF) showed noninferior efficacy to treatment with the standard-care

29 ntrations (GMCs) for vaccine types were only noninferior for 2 versus 3 doses for HPV-18 (at 2-3 year

30 GMCs for HPV-16/18 were not noninferior for 2 versus 3 doses, except for HPV-18 (at

31 % confidence interval: 0.80, 0.91]), FOM was noninferior for all lower-dose configurations except for

32 in the standard group (P = 0.0004), and was noninferior for neutrophil gelatinase-associated lipocal

33 n with missed adenomas greater than 5 mm was noninferior for segments with BBPS scores of 2 (5.2%) vs

34 We postulated that the miss rate was noninferior for segments with BBPS scores of 2 vs those

35 ate from baseline to month 6 (Nankivell) was noninferior for TacHexal versus Prograf using observed v

36 (HPV-16/18/31/33/45), the avidity index was noninferior for the 2-dose compared with the 3-dose sche

37 biodegradable polymer-based O-SES was found noninferior for the primary end point in-stent late lume

38 ed with up-titration of glargine resulted in noninferior HbA1c levels, with secondary analyses indica

39 PFS was noninferior (HR, 1.00; 95% CI, 0.65 to 1.53) and the inc

40 The lower threshold would be considered noninferior if scores were less than 7.5 points lower th

41 ipants, humoral immune response to HZ/su was noninferior in HZ-PreVac compared with HZ-NonVac (adjust

42 DTG/3TC was noninferior in maintaining virologic suppression vs a TA

43 AREDS/AREDS2 was superior in some cases and noninferior in others to clinical human grading (retinal

44 s associated with shorter length of stay and noninferior long-term survival when compared with open l

45 included in the international, multicenter, noninferior, open-label, randomized COLOR II trial were

46 To determine whether insulin degludec is noninferior or superior to insulin glargine U100 in redu

47 Imipenem/cilastatin/relebactam was noninferior (P < .001) to piperacillin/tazobactam for bo

48 The T&E regimen was noninferior (P < 0.001) to the monthly regimen, with a l

49 for surgical residents were associated with noninferior patient outcomes and no significant differen

50 s (size-specific dose estimate, 0.9 mGy) had noninferior performance compared with routine dose in de

51 By intention-to-treat BP-DES were noninferior (predefined margin, 3.80%) compared with DP-

52 whether people treated in primary care had a noninferior rate of sustained virologic response at Week

53 NSAID use resulted in noninferior rates of pleurodesis efficacy at 3 months.

54 The ABSORB III trial demonstrated noninferior rates of target lesion failure (cardiac deat

55 The ABSORB III trial demonstrated noninferior rates of target lesion failure (cardiac deat

56 piride over a median 6.3 years resulted in a noninferior risk of a composite cardiovascular outcome.

57 th placebo added to usual care resulted in a noninferior risk of a composite CV outcome over a median

58 proved specificity (P = .002) and obtained a noninferior sensitivity with a margin of 5% (P < .001).

59 10, a randomized clinical trial demonstrated noninferior survival for patients with advanced ovarian

60 unavir/ritonavir and lamivudine demonstrated noninferior therapeutic efficacy and similar tolerabilit

61 ng a ratio of 1.06 (95% CI, 1.02-1.10) and a noninferior time adequately sedated.

62 Our data suggest that (18)F-DCFPyL is noninferior to (68)Ga-PSMA-HBED-CC, while offering the a

63 usion: Our data suggest that (18)F-DCFPyL is noninferior to (68)Ga-PSMA-HBED-CC, while offering the a

64 nibizumab resulted in visual acuity that was noninferior to (not worse than) PRP treatment at 2 years

65 id (200 mg once daily) has been proven to be noninferior to 10 days of linezolid (600 mg twice daily)

66 re day 7, an antibiotic course of 7 days was noninferior to 14 days.

67 elet treatment with DAPT for 6 months may be noninferior to 24-month DAPT in aspirin-sensitive patien

68 in women aged 15-25 years and 2D (M0,12) was noninferior to 2D (M0,6).

69 ratios (cLIA) for both 2D and 3D girls were noninferior to 3 doses in women for HPV6/11/16/18.

70 After BEACOPPbaseline, 20 Gy IF-RT was noninferior to 30 Gy (10-year PFS, 84% v 84%; HR, 1.0; 9

71 /16/18 after 2D or 3D of 4vHPV in girls were noninferior to 3D in adult women up to 120 months postva

72 th 2D regimens in girls aged 9-14 years were noninferior to 3D in women aged 15-25 years and 2D (M0,1

73 licited HPV-16/18 immune responses that were noninferior to 3D in women aged 15-25 years.

74 A single 1200-mg dose of oritavancin was noninferior to 7-10 days of vancomycin in treating ABSSS

75 patients with CABP, 5-day oral lefamulin was noninferior to 7-day oral moxifloxacin with respect to e

76 f once-weekly rifapentine plus isoniazid was noninferior to 9 months of isoniazid alone for preventin

77 th regimen of rifapentine plus isoniazid was noninferior to 9 months of isoniazid alone for preventin

78 Dalbavancin delivered as a single dose was noninferior to a 2-dose regimen (81.4% vs 84.2%; differe

79 A single 1500-mg infusion of dalbavancin is noninferior to a 2-dose regimen, has a similar safety pr

80 orbable scaffold has been demonstrated to be noninferior to a contemporary metallic drug-eluting sten

81 ith about 5 hours of therapeutic contact was noninferior to a conventional course of CBT that provide

82 d within 24 hours, a lower PEEP strategy was noninferior to a higher PEEP strategy with regard to the

83 (98.9%) or 8 weeks (97.8%) of treatment were noninferior to a historical control (98%).

84 nclusion Autologous blood patch injection is noninferior to a hydrogel plug regarding the rate of pne

85 strategy regarding red-cell transfusion was noninferior to a liberal strategy with respect to the co

86 nes and aminoglycosides, a short regimen was noninferior to a long regimen with respect to the primar

87 investigate whether the BioFreedom stent is noninferior to a modern ultrathin strut biodegradable po

88 garding visual outcomes, the T&E regimen was noninferior to a monthly dosing regimen.

89 reatment threshold (36 mg per deciliter) was noninferior to a traditional threshold (47 mg per decili

90 per deciliter [2.0 mmol per liter]) would be noninferior to a traditional threshold (treatment at a g

91 rom baseline (letters) with brolucizumab was noninferior to aflibercept at week 12 (5.75 and 6.89, re

92 To investigate whether bevacizumab is noninferior to aflibercept for the treatment of macular

93 vein occlusion, intravitreal bevacizumab was noninferior to aflibercept with respect to visual acuity

94 rdial, centrifugal-flow LVAD was found to be noninferior to an axial-flow LVAD with respect to surviv

95 n Cameroon, a dolutegravir-based regimen was noninferior to an EFV400-based reference regimen with re

96 ether a cardiovascular MRI-based strategy is noninferior to an FFR-based strategy with respect to maj

97 an iFR-guided revascularization strategy was noninferior to an FFR-guided revascularization strategy

98 hesis was that an INR target of 1.8 would be noninferior to an INR target of 2.5, using a noninferior

99 Antibiotics were noninferior to appendectomy on the basis of 30-day EQ-5D

100 treatment of appendicitis, antibiotics were noninferior to appendectomy on the basis of results of a

101 High-dose unilateral ECT was noninferior to bitemporal ECT regarding the 24-item HAM-

102 t forgoing bridging anticoagulation would be noninferior to bridging with low-molecular-weight hepari

103 ment, PCI with everolimus-eluting stents was noninferior to CABG with respect to the rate of the comp

104 Trials concluding IAD is noninferior to CAD were based on wide NIMs that included

105 monotherapy with once-daily dolutegravir was noninferior to cART.

106 Tests of noninferiority showed that TCC was noninferior to CBT-I at 15 months ( P = .02) and at mont

107 Here, we evaluated whether TCC is noninferior to CBT-I for the treatment of insomnia in su

108 nt meditation, was found to be statistically noninferior to CBT-I, the gold standard for behavioral t

109 CCTA/rCTP is noninferior to CCTA/SPECT-MPI to discriminate ACS and pr

110 acic echocardiography and lung ultrasound is noninferior to chest radiograph when used to accurately

111 cic echocardiography and lung ultrasound are noninferior to chest x-ray for screening of pneumothorax

112 is not available leads to outcomes that are noninferior to CIC follow-up.

113 Etelcalcetide was noninferior to cinacalcet on the primary end point.

114 The short-course radiotherapy was noninferior to commonly used radiotherapy.

115 n, changing to oral antibiotic treatment was noninferior to continued intravenous antibiotic treatmen

116 d to determine whether oral antibiotics were noninferior to continued intravenous antibiotics for KLA

117 EFA in all short-course arms was noninferior to control.

118 Filtered sunlight was noninferior to conventional phototherapy for the treatme

119 Nasal high-flow therapy was not shown to be noninferior to CPAP and resulted in a significantly high

120 opulmonary bypass, fibrinogen concentrate is noninferior to cryoprecipitate with regard to number of

121 Rituximab was noninferior to cyclosporine in inducing complete or part

122 rior cell grades for both XG-102 groups were noninferior to dexamethasone (-0.054 anterior cell grade

123 on of XG-102 at the end of ocular surgery is noninferior to dexamethasone eye drops in the treatment

124 To investigate whether distal diuretics are noninferior to dietary sodium restriction in reducing BP

125 Distal diuretics are noninferior to dietary sodium restriction in reducing BP

126 f-administered therapy without reminders was noninferior to direct observation in the United States;

127 oke and increased risk of bleeding, LAAC was noninferior to DOAC in preventing major AF-related cardi

128 Pazopanib was noninferior to doxorubicin, rendering pazopanib a putati

129 RK/T, Holladay 2, and Hoffer Q formulas were noninferior to each other.

130 al fibrillation, a wait-and-see approach was noninferior to early cardioversion in achieving a return

131 ed these 2 stents and has shown that ZES was noninferior to EES at 12-month for the primary end point

132 ne expression profiling (GEP) blood test was noninferior to EMB between 6 and 60 months post transpla

133 Stenting was noninferior to endarterectomy with regard to the primary

134 isk for surgical complications, stenting was noninferior to endarterectomy with regard to the rate of

135 Rivaroxaban may be noninferior to enoxaparin with regard to the prevention

136 rity was planned if rivaroxaban proved to be noninferior to enoxaparin.

137 Therapies) trial found triple therapy to be noninferior to etanercept-methotrexate in patients with

138 clitaxel-eluting stents were not shown to be noninferior to everolimus-eluting stents, and they resul

139 sing mixed linear models showed that PBT was noninferior to FBT on all outcomes at 6-, 12-, and 18-mo

140 Although withholding FDP was found to be noninferior to FDP for the study population as a whole (

141 Withholding FDP was noninferior to FDP in holes </=400 mum in diameter.

142 coronary revascularization than FFR and was noninferior to FFR with respect to major adverse cardiac

143 We aimed to evaluate whether iFR is noninferior to FFR with respect to the rate of subsequen

144 Seroconversion with fIPV im was noninferior to fIPV id for all serotypes.

145 ment duration and fixed 7-day treatment were noninferior to fixed 14-day treatment.

146 risk for cardiovascular events, degludec was noninferior to glargine with respect to the incidence of

147 At moderate doses, celecoxib was found to be noninferior to ibuprofen or naproxen with regard to card

148 effectiveness of home-based HT with a CD is noninferior to iHT performed by therapists in pediatric

149 Therapy (ENCORE), at 1 year, eliglustat was noninferior to imiglucerase enzyme therapy in maintainin

150 e 1-year follow-up, telephone counseling was noninferior to in-person counseling for all psychosocial

151 hypothesized that external cardioversion is noninferior to internal cardioversion for safety, and su

152 ment of primary spontaneous pneumothorax was noninferior to interventional management, with a lower r

153 estigated whether oral antibiotic therapy is noninferior to intravenous antibiotic therapy for this i

154 Oral antibiotic therapy was noninferior to intravenous antibiotic therapy when used

155 Oral antibiotics were noninferior to intravenous antibiotics for the early tre

156 atment in bone and joint infection (BJI), is noninferior to intravenous therapy.

157 Intravenous-to-oral solithromycin was noninferior to intravenous-to-oral moxifloxacin.

158 o assess whether intravitreal bevacizumab is noninferior to intravitreal aflibercept for treatment of

159 o assess whether intravitreal bevacizumab is noninferior to intravitreal aflibercept for treatment of

160 Intravitreal dexamethasone implant was noninferior to ITA at 8 weeks (PropBL IDI/PropBL ITA, HR

161 In this randomized trial, POEM was noninferior to LHM plus Dor's fundoplication in controll

162 population, omadacycline (316 patients) was noninferior to linezolid (311 patients) with respect to

163 Omadacycline was noninferior to linezolid for the treatment of acute bact

164 Omadacycline was noninferior to linezolid using the Food and Drug Adminis

165 Omadacycline also was noninferior to linezolid with respect to investigator-as

166 ted evidence that the Watchman device may be noninferior to long-term OAC in selected patients.

167 Sulfur hexafluoride gas was found to be noninferior to longer-acting gases (95% confidence inter

168 Sulfur hexafluoride gas tamponade was noninferior to longer-acting gases in the surgical manag

169 Ceftazidime-avibactam plus metronidazole was noninferior to meropenem across all primary analysis pop

170 Once-daily plazomicin was noninferior to meropenem for the treatment of complicate

171 eftolozane/tazobactam plus metronidazole was noninferior to meropenem in adult patients with cIAI, in

172 Treatment with eravacycline was noninferior to meropenem in adult patients with cIAI, in

173 eftolozane/tazobactam plus metronidazole was noninferior to meropenem in the primary (83.0% [323/389]

174 Eravacycline was noninferior to meropenem in the primary endpoint (177/19

175 Ceftazidime-avibactam plus metronidazole was noninferior to meropenem in the treatment of complicated

176 Plazomicin was noninferior to meropenem with respect to the primary eff

177 ce for as-needed ranibizumab injections, was noninferior to monthly ranibizumab as well as to as-need

178 that zoledronic acid (ZA) every 3 months was noninferior to monthly ZA in reducing the risks of SREs.

179 Omadacycline was noninferior to moxifloxacin for early clinical response

180 Lefamulin was noninferior to moxifloxacin for ECR (87.3% vs 90.2%, res

181 Lefamulin was noninferior to moxifloxacin for the primary efficacy end

182 Omadacycline was noninferior to moxifloxacin for the treatment of communi

183 Omadacycline was noninferior to moxifloxacin, based on a new ECR endpoint

184 tient-controlled analgesia (IV-PCA) could be noninferior to multimodal thoracic epidural analgesia (T

185 whether HHHFNC provides respiratory support noninferior to nasal continuous positive airway pressure

186 The use of HHHFNC was noninferior to nCPAP with regard to the primary outcome:

187 t if high-flow conditioned oxygen therapy is noninferior to NIV for preventing postextubation respira

188 omy to date, and it demonstrates that RPD is noninferior to OPD in terms of pancreatic fistula develo

189 Robotic pancreatoduodenectomy was also noninferior to OPD in terms of the occurrence of any com

190 Laparoscopy was noninferior to open surgery for rectal cancer in terms o

191 ong-acting cabotegravir plus rilpivirine was noninferior to oral therapy with dolutegravir-abacavir-l

192 ith sentinel lymph node dissection alone was noninferior to overall survival for those treated with a

193 s, high-definition, white-light endoscopy is noninferior to pancolonic chromoendoscopy for detection

194 d that CNN-based diagnosis of SRH images was noninferior to pathologist-based interpretation of conve

195 edure, forgoing bridging anticoagulation was noninferior to perioperative bridging with low-molecular

196 e-photon emission tomography was found to be noninferior to PET in terms of specificity (P < .001) bu

197 ncreased cardiovascular risk, aclidinium was noninferior to placebo for risk of MACE over 3 years.

198 Sitagliptin was noninferior to placebo for the primary composite cardiov

199 We hypothesized that semaglutide would be noninferior to placebo for the primary outcome.

200 The DPP4i sitagliptin has been shown to be noninferior to placebo with regard to primary and second

201 ary hypothesis was that liraglutide would be noninferior to placebo with regard to the primary outcom

202 ic cardiovascular disease, ertugliflozin was noninferior to placebo with respect to major adverse car

203 hat exenatide, administered once weekly, was noninferior to placebo with respect to safety (P<0.001 f

204 xenatide, administered once weekly, would be noninferior to placebo with respect to safety and superi

205 To determine whether sitagliptin was noninferior to placebo, we used a relative risk of 1.3 a

206 PF-AES were clinically noninferior to PP-ZES (risk difference, 0.5%; upper limi

207 PF-AES were noninferior to PP-ZES regarding target-lesion failure at

208 Nepafenac was noninferior to prednisolone in controlling inflammation

209 Nepafenac was noninferior to prednisolone with regard to inflammation

210 ia, although tafenoquine was not shown to be noninferior to primaquine.

211 chemotherapy and interval cytoreduction are noninferior to primary cytoreduction and adjuvant chemot

212 To determine whether yoga is noninferior to PT for cLBP.

213 alized yoga program for nonspecific cLBP was noninferior to PT for function and pain.

214 o determine whether cryoballoon ablation was noninferior to radiofrequency ablation in symptomatic pa

215 s randomized trial, cryoballoon ablation was noninferior to radiofrequency ablation with respect to e

216 change in visual acuity, that bevacizumab is noninferior to ranibizumab for patients with ME resultin

217 Ranibizumab with laser was noninferior to ranibizumab monotherapy (mean average BCV

218 safety and efficacy of VGLB ablation proved noninferior to RFA for the treatment of paroxysmal AF.

219 -dose FBP images without ANLM or SAFIRE were noninferior to routine-dose images for abdominal CT but

220 TAVR was noninferior to SAVR when compared using both trial and c

221 vir-velpatasvir-voxilaprevir for 8 weeks was noninferior to sofosbuvir-velpatasvir for 12 weeks, but

222 T, whether or not followed by sorafenib, was noninferior to sorafenib (10.2 and 9.2 mo [hazard ratio,

223 as monotherapy or followed by sorafenib, is noninferior to sorafenib and to compare safety profiles

224 SIRT as initial therapy for advanced HCC is noninferior to sorafenib in terms of OS and offers a bet

225 diethylcarbamazine plus albendazole [IDA] is noninferior to standard 3 annual doses of ivermectin plu

226 Drug-coated balloons were noninferior to standard balloons with respect to the pri

227 Micafungin was noninferior to standard care as antifungal prophylaxis i

228 vitamin K oral anticoagulants, were at least noninferior to standard care in the prevention of most p

229 ection of oral P2Y(12) inhibitor therapy was noninferior to standard treatment with ticagrelor or pra

230 In conclusion, rituximab was noninferior to steroids for the treatment of juvenile SD

231 r sites in Italy tested whether rituximab is noninferior to steroids in maintaining remission in juve

232 l treatment with beta-lactam monotherapy was noninferior to strategies with a beta-lactam-macrolide c

233 Oral apixaban was noninferior to subcutaneous dalteparin for the treatment

234 Oral edoxaban was noninferior to subcutaneous dalteparin with respect to t

235 elf-expanding supraannular bioprosthesis was noninferior to surgery with respect to the composite end

236 IV-PCA was noninferior to TEA for the treatment of postoperative pa

237 y response to HPV-6, 11, 16, and 18 that was noninferior to that generated by the qHPV vaccine.

238 Sleep duration in flexible programs was noninferior to that in standard programs (between-group

239 ial year vs. 12.6% in the pretrial year) was noninferior to that in the standard programs (12.2% in t

240 enhanced CT has a breakthrough reaction rate noninferior to that of a 13-hour oral premedication regi

241 aterial-enhanced computed tomography (CT) is noninferior to that of a traditional 13-hour oral regime

242 rneal donor tissue preserved 8 to 14 days is noninferior to that of donor tissue preserved 7 days or

243 ography with FBP and SAFIRE is statistically noninferior to that of full-dose CT enterography for act

244 The AUC was noninferior to that of human retinal specialists.

245 The EFS for SR patients in AAML0631 was noninferior to that of patients in the AIDA 0493 histori

246 efficacy of tafenoquine was not shown to be noninferior to that of primaquine (odds ratio for recurr

247 found that the efficacy of isavuconazole was noninferior to that of voriconazole.

248 out axillary lymph node dissection (ALND) is noninferior to that of women treated with axillary disse

249 confidence interval: 0.8%, 5.7%), which was noninferior to the 2.1% (13 of 626 patients; 95% confide

250 oth 2-dose schedules in young girls remained noninferior to the 3-dose schedule in women up to study

251 nths 54 and 64, the 2-dose schedule remained noninferior to the 3-dose schedule.

252 the 2D_M0,6 and 2D_M0,12 schedules remained noninferior to the 3D_M0,1,6 schedule in terms of seroco

253 62.1% treatment success in the CD group was noninferior to the 71.0% in the iHT group (difference, -

254 The MGI was noninferior to the BGI in lowering IOP.

255 The MGI was noninferior to the BGI when comparing postoperative IOP,

256 The MGI could not be deemed noninferior to the BGI with regard to time until device

257 hin-strut sirolimus-eluting Orsiro stent was noninferior to the biolimus-eluting Nobori stent in unse

258 in the extended-release naltrexone group was noninferior to the buprenorphine-naloxone group (differe

259 utcomes of patients followed in the TMVC are noninferior to the CIC.

260 very 12 weeks regimen of zoledronic acid was noninferior to the every 4 weeks regimen for the proport

261 showed a "simplified" artesunate regimen was noninferior to the existing World Health Organization re

262 .908; SAFIRE 3, 0.935; SAFIRE 4, 0.924) were noninferior to the mean AUC with full-dose FBP scans (0.

263 The rate of MACCE (7.3%) was noninferior to the performance goal (18.3%, pnoninferior

264 The respiratory polygraphy protocol was noninferior to the polysomnography protocol based on the

265 ree lower-dose alternatives were found to be noninferior to the routine-dose FBP.

266 N1) during 2012-2013 (the HD formulation was noninferior to the SD formulation for influenza A[H1N1]

267 The drug-coated balloon was noninferior to the standard balloon with respect to safe

268 essment of LV function with SSIR at 3.0 T is noninferior to the standard of reference irrespective of

269 rative urine output target of 0.2 mL/kg/h is noninferior to the standard target of 0.5 mL/kg/h and re

270 dicate that the DTG-containing regimens were noninferior to the standard-care regimen.

271 ication for pacing, the subcutaneous ICD was noninferior to the transvenous ICD with respect to devic

272 We hypothesized that VO training would be noninferior to the VSI approach with respect to chest co

273 wn that antibody responses after 2 doses are noninferior to those after 3 doses, suggesting that 2 an

274 Diagnoses from WSI were noninferior to those from TM.

275 body responses to HPV-6, 11, 16, and 18 were noninferior to those generated by the qHPV vaccine.

276 OCKET-1, post hoc outcome measure). was also noninferior to timolol (ROCKET-2).

277 LBN 0.024% QD in the evening was noninferior to timolol 0.5% BID over 3 months of treatme

278 first-in-class IOP-lowering medication, was noninferior to timolol BID and was associated with toler

279 hat mean IOP reduction with LBN was not only noninferior to timolol but significantly greater (P </=

280 h dose strengths of bimatoprost implant were noninferior to timolol in IOP lowering after each admini

281 ine intraocular pressure (P < .001), and was noninferior to timolol in the per-protocol population wi

282 for chest-indrawing pneumonia for 3 days was noninferior to treatment for 5 days.

283 ll depletion with rituximab may therefore be noninferior to treatment with cyclosporine for inducing

284 g amoxicillin to treat this condition may be noninferior to using amoxicillin.

285 In 2 phase 3 clinical trials, telavancin was noninferior to vancomycin in patients with HAP due to gr

286 TARGET demonstrated that ceftobiprole is noninferior to vancomycin/aztreonam in the treatment of

287 blood samples collected by finger-prick was noninferior to venous blood collected in PAXgene tubes.

288 eous left atrial appendage closure (LAAC) is noninferior to vitamin K antagonists (VKAs) for preventi

289 xaban, apixaban, dabigatran, and edoxaban-is noninferior to warfarin (absolute rate of recurrent VTE

290 on 48), the factor Xa inhibitor edoxaban was noninferior to warfarin in preventing stroke or systemic

291 Direct oral anticoagulants are noninferior to warfarin with regard to efficacy and are

292 bioprosthetic mitral valve, rivaroxaban was noninferior to warfarin with respect to the mean time un

293 r Xa inhibitor with 50% renal clearance, was noninferior to well-managed warfarin for stroke or syste

294 O-SES was noninferior to X-EES for the primary end point (0.10+/-0

295 ledronic acid administered every 12 weeks is noninferior to zoledronic acid administered every 4 week

296 e whether zoledronic acid every 12 weeks was noninferior to zoledronic acid every 4 weeks in patients

297 of children was comparable to (specifically, noninferior to) annual treatment of the entire community

298 7-100) of people treated in primary care was noninferior when compared to historical controls (85% as

299 ion reduction, compared with usual care, was noninferior with regard to systolic blood pressure contr

300 ing the 6 months after the procedure and was noninferior with respect to access circuit-related serio